MHC restriction and antigen characterization of mucosal CD8aa TCRab IEL
粘膜 CD8aa TCRab IEL 的 MHC 限制和抗原表征
基本信息
- 批准号:8316172
- 负责人:
- 金额:$ 22.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-15 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAntigen TargetingAntigen-Presenting CellsAntigensApoptosisBiological AssayBiologyBone Marrow CellsCD8B1 geneCell LineCellsCellular StressCellular biologyChimera organismCloningConsensusDataDendritic CellsDevelopmentEpithelial CellsFractionationGenerationsHigh Pressure Liquid ChromatographyHistocompatibility Antigens Class IIHourHybridomasImmuneImmune responseImmune systemImmunityIn VitroInflammatory Bowel DiseasesIntestinesKnock-outLeadLinkLymphocyteLymphocyte BiologyLymphocyte SubsetLymphocyte antigenMajor Histocompatibility ComplexMass Spectrum AnalysisMethodsModalityModelingMouse StrainsMusPathway interactionsPeptidesPhenotypePlayPopulationPopulation HeterogeneityPreparationProcessResearchRetroviridaeRoleSignal TransductionSmall IntestinesSpecificitySystemT-Cell Antigen Receptor SpecificityT-Cell ReceptorT-LymphocyteThymomaThymus GlandTransgenic MiceTransgenic Modelbacterial lysatebaseclinical practiceexperiencefood antigenin vivoinsightintraepithelialnovel therapeuticspathogenthymocyte
项目摘要
DESCRIPTION (provided by applicant): Although intestinal intraepithelial lymphocytes (IEL) constitute one of the largest T cell compartments of the body our understanding of their development and function is conspicuously limited. The objective of the presented study is to provide insight into the most fundamental aspects of IEL biology, addressing the question of their antigen-major histocompatibility complex (MHC) restriction and potentially also their antigen specificity. Our research will focus on CD8aa TCRa¿ IEL populations. In the first part of this project, we will immortalize IEL by fusing them with a thymoma cell line to generate T-cell hybridomas that will be subsequently used in a number of functional assays. Initially, they will be stimulated with different antigen preparations (such as intraepithelial cell lysates, bacterial lysates, food antigen preparations) presented by a variety of cells including various populations of dendritic cells and epithelial cells. In case of positive activation, the identification of the restricting MHC molecules will be investigated using antigen-presenting cells isolated from various MHC deficient mice strains. Antigen identification will then be attempted by HPLC sequential fractionations and mass spectrometry. In the second aim, we will sequence and clone the TCRa- and -¿ chains of the hybridomas generated previously. We will then retrovirally transfect these TCRs into bone marrow cells (BM) and inject them into various lethally irradiated MHC hosts. Analysis of the different BM chimeras should allow us to define the MHC restriction of CD8aa TCRa¿ IELs in vivo. Both aims are complementary and will lead to the identification of the antigen and MHC restriction of CD8aa TCRa¿ IELs. The results of this study will provide us with a tremendous amount of new and important information regarding the biology of CD8aa TCRa¿ IELs. Better understanding of the intestinal immune system holds promise of the development of novel therapeutic modalities for a number of intestinal inflammatory disorders.
描述(由申请人提供):虽然肠上皮内淋巴细胞(IEL)构成人体最大的T细胞区室之一,但我们对其发育和功能的理解明显有限。本研究的目的是深入了解IEL生物学的最基本方面,解决其抗原-主要组织相容性复合体(MHC)限制性问题,并可能解决其抗原特异性问题。我们的研究将集中在CD 8aa TCR α IEL人群。在本项目的第一部分,我们将通过将IEL与胸腺瘤细胞系融合来产生T细胞杂交瘤,从而使IEL永生化,所述T细胞杂交瘤随后将用于许多功能测定。最初,它们将用不同的抗原制剂(例如上皮内细胞裂解物、细菌裂解物、食物抗原制剂)刺激,所述抗原制剂由包括各种树突细胞和上皮细胞群体的各种细胞呈递。在阳性激活的情况下,将使用从各种MHC缺陷小鼠品系分离的抗原呈递细胞研究限制性MHC分子的鉴定。然后尝试通过HPLC连续分馏和质谱法进行抗原鉴定。在第二个目标中,我们将测序和克隆先前产生的杂交瘤的TCR α和TCR β链。然后,我们将逆转录病毒介导这些TCR进入骨髓细胞(BM),并将它们注射到各种致死辐射的MHC宿主中。分析不同的BM嵌合体应该使我们能够定义体内CD 8aa TCR α IEL的MHC限制。这两个目标是互补的,并将导致识别抗原和CD 8aa TCR α IEL的MHC限制。这项研究的结果将为我们提供大量关于CD 8aa TCR α IELS生物学的新的重要信息。对肠道免疫系统的更好理解有望为许多肠道炎症性疾病开发新的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Florence Lambolez其他文献
Florence Lambolez的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Florence Lambolez', 18)}}的其他基金
Thymic development and MHC restriction of CD8aa TCRab intraepithelial lymphocytes
CD8aa TCRab 上皮内淋巴细胞的胸腺发育和 MHC 限制
- 批准号:
8285724 - 财政年份:2012
- 资助金额:
$ 22.73万 - 项目类别:
Thymic development and MHC restriction of CD8aa TCRab intraepithelial lymphocytes
CD8aa TCRab 上皮内淋巴细胞的胸腺发育和 MHC 限制
- 批准号:
8534699 - 财政年份:2012
- 资助金额:
$ 22.73万 - 项目类别:
MHC restriction and antigen characterization of mucosal CD8aa TCRab IEL
粘膜 CD8aa TCRab IEL 的 MHC 限制和抗原表征
- 批准号:
8114949 - 财政年份:2011
- 资助金额:
$ 22.73万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 22.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 22.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 22.73万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 22.73万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 22.73万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 22.73万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 22.73万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 22.73万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 22.73万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 22.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)